Company intelligence / Profile preview
Davipharm
- Ownership
- Private
- Employees
- ~250
- Development stage
- Commercial
Overview
Davipharm manufactures high-quality generic pharmaceuticals with a focus on solid oral dosage forms. It was the first company in Vietnam to receive EU-GMP certification for its highly active solid drug production line during the COVID pandemic. Its portfolio includes at least 28 highly active medicines targeting multiple cancers. The company has expanded exports to Southeast Asia and continues to invest in R&D and manufacturing upgrades.[6][3][1][2][5] No clinical trial results are reported as it focuses on generics.
- Therapeutic areas
- OncologyOther
- Modalities
- small molecules (solid oral forms including tablets and capsules; cytotoxic/cytostatic drugs)[5]oncology drugs[5]generic medicines[3][5]
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Davipharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Davipharm.